<qa>  What is the name of the VERSUS NON-ADJUVANTED VERSIMMUNOGENICITY, SAFETY, AND TOLERABILITY OF AN MF59-ADJUVANTED VERSUS NON-ADJUVANTED INFLUENZA VACCINES IN PATIENTS WITH CHRONIC PULMONARY DISEASE, CHRONIC HEART DISEASE, OR DIABETES MELLITUS: 